AU2009265362B2 - Chemical compounds 251 - Google Patents

Chemical compounds 251 Download PDF

Info

Publication number
AU2009265362B2
AU2009265362B2 AU2009265362A AU2009265362A AU2009265362B2 AU 2009265362 B2 AU2009265362 B2 AU 2009265362B2 AU 2009265362 A AU2009265362 A AU 2009265362A AU 2009265362 A AU2009265362 A AU 2009265362A AU 2009265362 B2 AU2009265362 B2 AU 2009265362B2
Authority
AU
Australia
Prior art keywords
dione
thiazolidine
phenyl
methylidene
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009265362A
Other languages
English (en)
Other versions
AU2009265362A1 (en
Inventor
Leslie Dakin
James Edward Dowling
Michelle Lamb
Jon Read
Qibin Su
Xiaolan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009265362(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2009265362A1 publication Critical patent/AU2009265362A1/en
Application granted granted Critical
Publication of AU2009265362B2 publication Critical patent/AU2009265362B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2009265362A 2008-07-02 2009-07-02 Chemical compounds 251 Ceased AU2009265362B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7763908P 2008-07-02 2008-07-02
US61/077,639 2008-07-02
US18327809P 2009-06-02 2009-06-02
US61/183,278 2009-06-02
PCT/GB2009/050773 WO2010001169A2 (en) 2008-07-02 2009-07-02 Chemical compounds 251

Publications (2)

Publication Number Publication Date
AU2009265362A1 AU2009265362A1 (en) 2010-01-07
AU2009265362B2 true AU2009265362B2 (en) 2012-07-19

Family

ID=41050276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009265362A Ceased AU2009265362B2 (en) 2008-07-02 2009-07-02 Chemical compounds 251

Country Status (27)

Country Link
US (2) US8901307B2 (enExample)
EP (1) EP2310010A2 (enExample)
JP (2) JP5261575B2 (enExample)
KR (1) KR20110031367A (enExample)
CN (2) CN102137666B (enExample)
AR (1) AR072791A1 (enExample)
AU (1) AU2009265362B2 (enExample)
BR (1) BRPI0914599A2 (enExample)
CA (1) CA2729557A1 (enExample)
CL (1) CL2010001636A1 (enExample)
CO (1) CO6341555A2 (enExample)
CR (1) CR20110016A (enExample)
DO (1) DOP2010000408A (enExample)
EA (1) EA018989B1 (enExample)
EC (1) ECSP10010735A (enExample)
HN (1) HN2010002786A (enExample)
IL (1) IL210127A0 (enExample)
MX (1) MX2010014233A (enExample)
MY (1) MY155961A (enExample)
NI (1) NI201100007A (enExample)
NZ (1) NZ590859A (enExample)
PE (1) PE20120304A1 (enExample)
SV (1) SV2011003786A (enExample)
TW (1) TWI461423B (enExample)
UY (1) UY31952A (enExample)
WO (1) WO2010001169A2 (enExample)
ZA (1) ZA201100844B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
EP2832727B1 (en) 2012-03-30 2016-09-07 Rohto Pharmaceutical Co., Ltd. Novel benzylidene azolidine derivative or salt thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2015046389A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
WO2015046390A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US20170145005A1 (en) * 2014-02-13 2017-05-25 The University Of Tokyo Kinase inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP5857104B2 (ja) * 2014-06-17 2016-02-10 ロート製薬株式会社 ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016100391A1 (en) 2014-12-15 2016-06-23 Prosetta Antiviral, Inc. 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds
CN105985298B (zh) * 2015-02-10 2018-02-23 湖南大学 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
CN106032365B (zh) * 2015-03-11 2018-03-23 湖南大学 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
DK3439667T3 (da) 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
IL321754A (en) * 2017-06-30 2025-08-01 Univ California Compositions and methods for modulating hair growth
WO2019090205A1 (en) 2017-11-06 2019-05-09 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
JP7491510B2 (ja) * 2018-04-26 2024-05-28 メディシナル バイオコンバージェンス リサーチ センター ｍＴＯＲ阻害剤としての新規化合物及びその用途
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12649736B2 (en) 2019-12-20 2026-06-09 The Regents Of The University Of California Synthesis of compounds to promote hair growth
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
CN116354901B (zh) * 2023-04-12 2024-04-26 郑州大学 一种噻唑烷二酮类化合物及其制备方法和应用
EP4746882A1 (en) 2023-07-20 2026-05-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Inhibitors of smndc1 and their therapeutic use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020120144A1 (en) * 2000-12-22 2002-08-29 Tsutomu Akama Telomerase inhibitors and methods of their use
WO2004093809A2 (en) * 2003-04-18 2004-11-04 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
NO305987B1 (no) 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
JP3668291B2 (ja) 1995-06-16 2005-07-06 久光製薬株式会社 新規なピペリジン誘導体
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ID29875A (id) * 1999-07-01 2001-10-18 Geron Corp Cs Penghambat-penghambat telomerase dan metode penggunaannya
TW593293B (en) * 1999-08-23 2004-06-21 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives
US6730687B1 (en) * 1999-08-23 2004-05-04 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2, 4-dione derivatives
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
CA2743756A1 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020120144A1 (en) * 2000-12-22 2002-08-29 Tsutomu Akama Telomerase inhibitors and methods of their use
WO2004093809A2 (en) * 2003-04-18 2004-11-04 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ottana, R., et al, Bioorganic & Medicinal Chemistry Letters, 2005, 15, 3930-3 *

Also Published As

Publication number Publication date
NZ590859A (en) 2012-08-31
TW201004949A (en) 2010-02-01
UY31952A (es) 2010-01-29
CN102137666A (zh) 2011-07-27
EP2310010A2 (en) 2011-04-20
US20110218182A1 (en) 2011-09-08
ZA201100844B (en) 2011-10-26
NI201100007A (es) 2011-12-15
JP5261575B2 (ja) 2013-08-14
KR20110031367A (ko) 2011-03-25
MY155961A (en) 2015-12-31
PE20120304A1 (es) 2012-04-22
TWI461423B (zh) 2014-11-21
JP2013139459A (ja) 2013-07-18
CO6341555A2 (es) 2011-11-21
JP2011526616A (ja) 2011-10-13
MX2010014233A (es) 2011-03-25
US8901307B2 (en) 2014-12-02
CN102137666B (zh) 2014-03-12
HN2010002786A (es) 2013-01-28
WO2010001169A2 (en) 2010-01-07
EA201100119A1 (ru) 2011-08-30
WO2010001169A3 (en) 2010-08-05
AR072791A1 (es) 2010-09-22
SV2011003786A (es) 2011-05-13
IL210127A0 (en) 2011-02-28
CA2729557A1 (en) 2010-01-07
CR20110016A (es) 2011-03-11
BRPI0914599A2 (pt) 2017-06-06
US20150051185A1 (en) 2015-02-19
ECSP10010735A (es) 2011-01-31
CL2010001636A1 (es) 2011-07-15
EA018989B1 (ru) 2013-12-30
AU2009265362A1 (en) 2010-01-07
DOP2010000408A (es) 2011-02-28
CN103804371A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
AU2009265362A1 (en) Chemical compounds 251
CA2598423C (en) Antibacterial piperidine derivatives
EP1910348B1 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU730607B2 (en) Aminothiazole inhibitors of cyclin dependent kinases
AU2014236812B2 (en) Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
AU2006290814B2 (en) 2-aniline-4-aryl substituted thiazole derivatives
CA2716365A1 (en) Heterocyclic urea derivatives and methods of use thereof-211
TW200932221A (en) Imidazole carbonyl compounds
CA2958262A1 (en) 1-cyano-pyrrolidine derivatives as deubiquitinase inhibitors (dub) and use thereof
AU2006297089A1 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
AU2008263580A1 (en) Piperidine compounds and uses thereof
WO2001044217A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
CA2637024A1 (en) Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
ES2742309T3 (es) Derivados de piperazina-imidazol y métodos de uso de los mismos para mejorar la farmacocinética de un fármaco
CA2725572A1 (en) Heterocyclic urea derivatives and methods of use thereof
AU2010277171B2 (en) Substituted benzamide derivatives as glucokinase (GK) activators
KR20220152159A (ko) 신규한 헤테로사이클 화합물 및 이의 용도
SA109300431B1 (ar) 5 – ميثيليدين – 1، 3 – ثيازوليدين – 2، 4 – ديونات بها استبدال كمثبطات لـ كيناز pim
HK1114376B (en) Antibacterial piperidine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired